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Abstract
Hypertensive disorders of pregnancy can have negative effects on both
mothers and neonates and are a major contributor to the increasing morbidity and
mortality affecting women pregnant women in the United States. Treatment
algorithms are available for treatment of hypertensive disorders of pregnancy
when treatment criteria are met. With proper use of these algorithms, healthcare
personnel can decrease the mortality and morbidity rates, which will increase
patient safety and decrease healthcare spending. This research project focused on
implementing The American College of Obstetricians and Gynecologists’
(ACOG) Labetalol treatment algorithm to treat patients diagnosed with severe
preeclampsia. Prior to implementation, data was collected from November 1,
2018 through January 31, 2019 and compared to data that was collected after
implementation, March 1, 2019 through May 31, 2019. Although compliance
with algorithm utilization decreased post implementation, the data proves that
with proper use, the Labetalol algorithm improves maternal blood pressures and
maternal outcomes.
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Improving Maternal Outcomes through Labetalol Algorithm Utilization for
Hypertensive Disorders of Pregnancy
Hypertensive disorders of pregnancy continue to be a key contributor to
mortality and morbidity in pregnant women in the United States. According to
Collier & Martin (2018), 7.4% of the 800 pregnancy related deaths that occur
each year are hypertension related. Not only do these disorders affect the
pregnant female, but they can have a negative effect on the neonate as well;
leading to preterm delivery, fetal growth restriction, and perinatal mortality. In
1993, hypertensive disorders affected approximately 500 per 10,000 delivery
hospitalizations compared to 900 per 10,000 in 2014 (CDC, 2018). Prompt
treatment of hypertensive disorders of pregnancy with a recommended
hypertensive medication use can decrease mortality and morbidity significantly if
implemented appropriately (ACOG, 2013).
Hypertensive disorders of pregnancy are separated into four different
classifications: chronic hypertension, gestational hypertension, preeclampsia and
eclampsia, chronic hypertension plus superimposed preeclampsia. Chronic
hypertension is defined as a systolic blood pressure (SBP) of greater than 140 or a
diastolic blood pressure (DBP) greater than 90 that occurs prior to pregnancy or
before 20 weeks gestation (American Congress of Obstetricians and
Gynecologists [ACOG], 2017). Gestational hypertension is defined as a SBP
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greater than 140 or a DBP greater than 90 that occurs after 20 weeks gestation
with no detection of proteinuria or other systemic signs/symptoms (ACOG, 2017).
Preeclampsia is defined as a SBP greater than 140 or a DBP of 90 with the
presence of proteinuria with or without systemic signs/symptoms; or the
presentation of systemic signs/symptoms/lab abnormalities in the absence of
proteinuria (ACOG, 2017). Chronic hypertension plus superimposed
preeclampsia is defined as the presence of chronic hypertension in addition to the
development of proteinuria or systemic signs/symptoms/lab abnormalities (See
Appendix A). Signs/symptoms of severe features of preeclampsia include: Two
severe blood pressure values obtained 15-60 minutes apart (SBP ≥ 160 or DBP ≥
110), persistent oliguria <500mL/24 hours, progressive renal insufficiency,
unremitting headache/visual disturbances, pulmonary edema, epigastric of right
upper quadrant (RUQ) pain, liver function tests (LFTs) > 2x the normal value,
platelets < 100,000, and the development of HELLP (hemolysis, elevated liver
enzymes, and low platelet counts) syndrome (ACOG, 2017). HELLP syndrome is
a life-threatening emergency.
Early detection of hypertensive disorders of pregnancy and appropriate
management can improve outcomes for both the pregnant female and the neonate.
Missed opportunities for recommended care contribute to the morbidity and
mortality. ACOG (2018) provides recommendations for diagnostic criteria,
treatment implications, medications (such as Labetalol), and monitoring. These
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recommendations are available for adoption and use in healthcare settings
throughout the United States and have proven to improve maternal and fetal
outcomes; however, many facilities lack an evidence-based maternal safety
bundle. The purpose of this project is to describe the care of pregnant women with
preeclampsia following the establishment of a protocol for use of the Labetalol
Algorithm.
The aims of this project were to establish baseline data on the number of
diagnosed preeclamptic patients that required treatment and how quickly
treatment was implemented; disseminate this data to physicians; and implement a
Labetalol Algorithm for treatment to improve maternal outcomes. On
completion, this project answered the following PICOT questions: In pregnant
women aged 18-45 at a Midwestern, suburban hospital,
1. What is the rate of the Labetalol Algorithm use by physicians when
criteria are met for preeclampsia?
2. When criteria are met, how quickly was treatment initiated?
3. When criteria are met for severe preeclampsia and treatment is
initiated, what is the rate of maternal blood pressure (BP)
improvement (return to patient baseline) pre and post algorithm?
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4. What is the rate of unplanned cesarean section when diagnosis of
preeclampsia is met before the Labetalol Algorithm was implemented
compared to after?
Review of Literature
Using truncation from October 1, 2010 to October 31, 2018, a literature
search was conducted using the following databases: CINAHL, Consumer Health
Complete, eBook Clinical Collection, MEDLINE, and Cochrane. The terms used
to conduct the search were “ACOG guidelines for hypertensive disorders of
pregnancy,” and “labetalol.” The search resulted 57 articles. After reviewing the
titles of the articles, 17 articles were chosen for abstract review based on
relevance to current pharmacological treatment recommendations. After further
review of these articles, five were excluded that only contained data on neonatal
outcomes during hypertensive emergencies in intrapartum patients.
The percentage of pregnancies affected by hypertensive disorders ranged
from 2.3% to 15% and are becoming more prevalent leading to an increased rate
of maternal mortality and morbidity (Anderson & Schmella, 2017; Arukumarlan
& Lighthouse, 2013; Cairns et al., 2016; Delgado De Pasquale, Velarde, Reyes, &
De La Ossa, 2014; Kelley, 2012; Vadhera & Simon, 2014). In the United States,
hypertensive disorders of pregnancy led to the death of 256 women in a three-year
time span, whereas eclampsia contributes to an estimated 50,000 deaths each year
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worldwide (Kelley, 2012). Between the years 1990-2015 in the United States,
maternal morality rose by as much as 27% (Collier & Martin, 2018).
ACOG’s report titled Hypertension in Pregnancy (2013) asserts that for
every maternal death due to hypertension that there is nearly 50-100 “near
misses” that result in serious health consequences for the mother which
contributes to the increasing costs of healthcare. Preeclampsia has the potential to
affect multiple organ systems leaving the woman susceptible to multiple
morbidities including: disseminated intravascular coagulation and respiratory,
cardiovascular, cerebrovascular, liver, kidney, uterine, and neurologic
complications (Anderson et al., 2013; Kelley, 2012). Kilpatrick et al. (2016)
compared morbidity rates between women with acute severe intrapartum
hypertension (2252 women) and women without severe hypertension (93,560
women). This retrospective cohort study found that severe maternal morbidities
were more frequent in women with severe hypertension (8.8%) as opposed to the
control group (2.3%). However, morbidities were present in only 8.6% of severe
hypertensive women that received treatment as opposed to 9.5% of the women
who didn’t receive treatment (Kilpatrick et al., 2016).
Risk factors for the development of hypertensive disorders of pregnancy
include: type 1 diabetes, gestational diabetes, other endocrine disorders, chronic
hypertension, kidney disease, connective tissue disease, multiple gestation, molar
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pregnancy, pre-pregnancy obesity, increased SBP in early pregnancy, extremes of
reproductive age, and a personal or family history of preeclampsia (Kelley, 2012).
In a cross-sectional study by Omani-Samani et al. (2017), the rate of preeclampsia
was higher in women who had a significant weight gain during their pregnancy
compared to women who gained an appropriate amount of weight. In this study,
the women with preeclampsia also showed higher rates of preterm birth, cesarean
section, and low birth weight infants.
In the past, there has been a lack of data on the safety and efficacy of
hypertensive drugs when used during pregnancy. This has contributed to the
large variations in practice guidelines globally. However, in recent years the
diagnosis and treatment of these disorders has been modified by ACOG (Vadhera
& Simon, 2014). Clark et al.’s report (2014) showed a significant reduction in
morbidity when order sets and protocols were implemented in facilities. Amro,
Moussa, Ashmini, & Sibai (2016) recommend a step-wise approach when
diagnosing and treating hypertensive disorders or pregnancy. Like Delgado De
Pasquale et al. (2014), Amro et al. (2016) recommend maxing out the use of one
medication prior to the use of a second antihypertensive. One prospective,
randomized, controlled trial utilized the Hydralazine and Labetalol protocols that
were identical to the example protocol provided in the Maternal Safety Bundle
provided by ACOG. A total of 261 participants were included in the study
(Hydralazine group: n=131 and Labetalol group: n=130). Prior to utilization of
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the algorithm, the initial SBP, DBP, and Mean Arterial Pressure (MAP) for the
Hydralazine group were as follows: 170 mmHg, 108 mmHg, and 128 mmHg.
After the protocol was implemented, their readings saw improvements: 144
mmHg (SBP), 91 mmHg (DBP), and 109 mmHg (MAP). The same held true for
the Labetalol group. The results prior to treatment were 172 mmHg (SBP), 107
mmHg (DBP), and 129 mmHg (MAP). After treatment, the values improved to
144 mmHg (SBP), 92 mmHg (DBP), and 109 mmHg (MAP). This study
concluded that Hydralazine or Labetalol has efficacy in controlling hypertensive
crises; however, the study concluded that there was persistent hypertension with
the use of Hydralazine (4.6%) compared to Labetalol (1.5%) (Delgado De
Pasquale et al., 2014). In the report Hypertension in Pregnancy by ACOG
(2013), it discusses that a Cochrane systematic review was conducted and that
there was no significant difference between the safety and efficacy of Labetalol
and Hydralazine. ACOG (2013) encourages the use of the drug that the physician
and facility is most familiar and comfortable with. For this project, the drug of
choice will be Labetalol due to familiarity and facility preference.
A cohort study by Xie et al. (2013) concluded that there has been an
increase use in antihypertensive drugs in pregnancy. According to the survey
conducted by Cairns et al. (2016), Labetalol was the most used antihypertensive
(91% of physicians). When compared to physicians, midwives stated that they
had a lower threshold for reducing antihypertensive medications than physicians.
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This study concluded that there is lack of consistency present in the management
of hypertensive patients. This may be the result of lack of evidence or guidance.
ACOG (2013) points out that there have been major advances in the knowledge
surrounding hypertensive disorders of pregnancy as well as new evidence that can
guide therapies and management. However, these new advancements have not
made their way into clinical practices yet. This is where the importance of
adopting and implementing treatment algorithms is crucial in the management of
these patients.
Treatment Recommendations
Prompt triage and assessment of pregnant women presenting with
hypertension is crucial for earlier diagnosis and treatment. A full of review of
systems should be performed to evaluate for cardiovascular symptoms (chest
pain), neurological symptoms (headache or visual disturbances), consciousness,
and difficulty breathing (Vadhera & Simon, 2014). When triaging a hypertensive
patient, baseline labs must be ordered and include: complete blood count (CBC)
with differential and platelet count, comprehensive metabolic panel (CMP),
urinalysis (UA), and a protein/creatinine ratio (ACOG, 2017; Kelley, 2012;
Vadhera & Simon, 2014). If end organ involvement is detected, pharmacologic
treatment and continuous monitoring is warranted. If the fetus is at a viable
gestation (>23 weeks), continuous fetal monitoring is recommended (ACOG,
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2017; Vadhera & Simon, 2014). When using the ACOG suggested Labetalol
algorithm, maternal blood pressure and pulse should be measured at least every
10 minutes until stable (ACOG, 2017; Vadhera & Simon, 2014). Once stable,
blood pressure should be monitored according to ACOG recommendations (see
Appendix D) (ACOG, 2017). If a diagnosis of severe preeclampsia is made and
pharmacologic treatment has been initiated, depending on gestation, consult
should be made to anesthesiology and maternal fetal medicine (Vadhera & Simon,
2014). Once diagnosis has been made, the objectives of treatment are the
prevention of seizures (eclampsia), tight blood pressure control, and the plan for
delivery (Peres, Mariana, & Cairrao, 2018). Maternal indications for delivery
include: “recurrent severe hypertension, recurrent symptoms of preeclampsia,
progressive renal insufficiency, persistent thrombocytopenia of HELLP
syndrome, pulmonary edema, eclampsia, suspected abruptio placentae, or
progressive labor or rupture of membranes” (ACOG, 2013, p.39). Transfer to a
tertiary care center may be necessary for services for the mother and neonate.
For this Quality Improvement (QI) project, a Plan-Do-Study-Act (PDSA)
framework was used to implement change. A PDSA is a four-stage cycle
approach that aids in the adaptation of changes. The first stage includes the
identification of the change followed by the testing of the change in the “do”
phase. The third stage identifies if the change was successful followed by making
necessary modifications in the fourth stage. PDSA approaches have demonstrated
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significant improvements in the care patients receive and their outcomes (Taylor
et al., 2013).
Methods
Design
A descriptive study design was for this quality improvement project. A
quality improvement process using the Plan-Do-Study-Act (PDSA) cycle was
used to implement the Labetalol Algorithm.
Setting
An inpatient women’s services unit at an organizationally owned hospital
in a suburb of a metropolitan area that is home to over three million people. This
unit employs more than 40 staff nurses and a team of more than 15 house
obstetricians. While not employed by the hospital, more than 30 private
physicians have practice rights to perform services at this setting. This unit is
open 24 hours a day and 365 days a year. Delivery services are offered to
pregnant patients who have completed at least the 32nd week of gestation.
Women who present to this unit who are less than 32 weeks gestation and are in
stable condition are transferred to a tertiary care center. This unit performs
approximately 75 deliveries per month and did 828 deliveries last year.
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Sample
A convenience sample of antepartum, intrapartum, or postpartum patients
whom are at least 32 weeks gestation or greater was used. The study period was
March 1st through May 31st. Inclusion criteria included pregnant females between
the ages of 18-45 who are greater than 32 weeks of gestation with a known or
newly diagnosed hypertensive disorder of pregnancy. Exclusion criteria included
non-pregnant females, pregnant females below the age of 18 and above the age of
45, and pregnant females less than 32 weeks gestation that require transfer to a
tertiary care center.
Approval Process
This project was approved by the Assistant Nurse Manager and Manager
at Progress West Hospital in the Women’s Services department at the beginning
of Semester 2018. The Labetalol algorithm was approved for use by the house
Obstetrician at Progress West as well as the Chief Medical Officer of the
department in October 2018. It was submitted to the University of Missouri-St.
Louis (UMSL) College of Nursing doctoral committee and UMSL graduate
school for approval. In addition, UMSL Institutional Review Board (IRB)
approval was obtained.
The benefits of this project included: standardization of evidence-based
care for hypertensive patients; decreased rates of eclampsia with prompt
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treatment; and increased awareness of treatment and management of hypertensive
disorders by all healthcare personnel.
Data Collection
Prior to implementation of the Labetalol algorithm, data was collected via
a retrospective chart review from November 1st 2018 through January 31st, 2019
to determine the current treatment of hypertensive antepartum females using the
data collection tool (Appendix E). The chart review contained data extracted
from the medical record that contained: weeks of gestation, vital signs, time from
diagnosis to treatment, medication and dose administered, and method of delivery
of the fetus. After implementation of the Labetalol algorithm, retrospective chart
review occurred once a week from March 1, 2019 to May 31, 2019 to allow for
statistical analysis of pre and post intervention data and dissemination of results.
Data collected was de-identified and coded. Charts reviewed prior to the
new protocol were labeled “B” for baseline beginning with B1. Charts reviewed
following implementation of the Labetalol algorithm were labeled “A” beginning
with A1. All data was stored on a password protected computer and encrypted
USB flash drive. This information was deleted after completion of the project in
July 2019.

LABETALOL ALGORITHM

15

Procedure
A team of key stakeholders which included the principal investigator,
nursing management, House Obstetrical Physician, Manager of Quality and
Education, and the Chief Medical Officer was formed October 2018. The team
reviewed the Anthem Blue Cross and Blue Shield Manual to Quality-In-Sights:
Hospital Incentive Program (Q-HIP) which provides a report of this facilities
performance along with data on best practice measures. For this unit’s report, it
was noted that an algorithm for monitoring and treating severe
preeclampsia/eclampsia was non-existent. The Labetalol Algorithm provided by
ACOG (see Appendix C) was adopted in March 2019 after project proposal
approval and was implemented into clinical practice.
Prior to implementation, the algorithm was presented to the lead house
obstetrician and the Chief Medical Officer of the unit for dissemination to the
attending physicians. An email was sent to the attending physicians discussing
the algorithm and the terms of the project. The contents of the email will contain
the algorithm, the implementation date, and the importance of their participation.
An email was also sent out to the nursing staff with the algorithm attached. A
flyer was placed in the employee bathroom to notify the employees that the
project was taking place and to have them check their emails for details.
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Results
From November 1, 2018 to January 31, 2019, there were 11 patients
diagnosed with a hypertensive disorder of pregnancy. Of these 11 patients, four
(n=4, 36.36%) met criteria for severe preeclampsia requiring treatment due to
blood pressure recordings. Two (n=2, 50%) patients were treated using the
recommended ACOG Labetalol algorithm driven by private physician orders, and
two (n=2, 50%) of these patients were treated using other orders given by their
attending. Three (n=3, 75%) of the patients that received treatment delivered
vaginally, while the other (n=1, 25%) delivered by repeat cesarean section
(Appendix A).
The two patients who were treated with the recommended algorithm, saw
a decrease in both systolic and diastolic blood pressure. The average decrease in
systolic and diastolic blood pressure was 19 mmHg and 6.5 mmHg respectively
(Appendix B). The timing of blood pressure recordings to the onset of treatment
for these two patients was an average of 37.5 minutes (Appendix C). The two
patients who were treated with other orders that didn’t follow the Labetalol
algorithm had an average increase in systolic blood pressure of 3 mmHg, and an
average decrease in diastolic blood pressure of 2 mmHg (Appendix B). The
average timing of treatment initiation was 49.5 minutes (Appendix C).

LABETALOL ALGORITHM

17

From March 1, 2019 to May 31, 2019, after algorithm implementation,
there were 11 patients that were diagnosed with a hypertensive disorder of
pregnancy. Of these 11 patients, three (n=3, 27.27%) met criteria for severe
preeclampsia requiring treatment due to blood pressure recordings. One (n=1,
9.09%) patient never met criteria, but orders following the algorithm were placed
in case blood pressures became severe. One (n=1, 33.33%) patient was treated
with the recommended ACOG Labetalol algorithm driven by nursing personnel,
house obstetrician, and attending physician; and two patients (n=2, 66.66%) were
treated with other orders given by their attending. Of the three patients that
received treatment, one (n=1, 33.33%) patient delivered vaginally, while the other
two (n=2, 66.66%) delivered by primary cesarean section (Appendix D). The one
patient who received treatment following the Labetalol algorithm saw a decrease
in systolic blood pressure of 22 mmHg, and a decrease in diastolic blood pressure
of 18 mmHg (Appendix E). The timing from blood pressure recording to the onset
of treatment was 30 minutes (Appendix F). The two patients who received
treatment using orders other than the Labetalol algorithm saw an average decrease
in systolic blood pressure of 8.5 mmHg and saw an average increase in diastolic
blood pressure of 7 mmHg (Appendix E). One of these patients was admitted to
the Intensive Care Unit with a diagnosis of pulmonary edema; a known
complication of severe preeclampsia. The average timing from blood pressure
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recordings to the onset of treatment for patients that weren’t treated using the
algorithm was 62 minutes (Appendix F).
Discussion
When criteria were met for the diagnosis and treatment of preeclampsia,
the rate of Labetalol algorithm use by physicians prior to implementation of
algorithm introduction to the unit was 50% (Appendix G). After algorithm
implementation on the unit, the rate of use by physicians was 33% (Appendix H).
The choice of algorithm use is ultimately up to the attending physician, regardless
of nursing and house obstetrician recommendations.
Prior to implementation, the average time of onset of treatment was 43.5
minutes. After the implementation, the average time for onset of treatment was
51.3 minutes. The physician should be contacted if one severe blood pressure is
obtained (≥160 mmHg systolic or ≥110 mmHg diastolic). If severe blood
pressure persists for more than 15 minutes or two severe pressures are obtained
within 15 minutes, treatment should be initiated. Because of the variation in
treatment guidelines and the potential to obtain non-consecutive severe blood
pressure reading at various times, treatment initiation times will vary.
When criteria were met for treatment of severe preeclampsia prior to
algorithm implementation, the average rate of maternal systolic blood pressure
improvement was 8.75 mmHg. However, an average increase of 4 mmHg was
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seen in the diastolic blood pressure. After the implementation period, the average
rate of maternal systolic and diastolic blood pressure improvement was 12.3
mmHg and 3.7 mmHg, respectively. It is important to note that although this
project’s algorithm was not implemented at this facility prior to March 2019,
some attending physicians still used the algorithm to treat their patients prior to
this date. It is also important to note that after the implementation period, not all
physicians used the algorithm to treat their patients. This skewed the results.
Before algorithm implementation, the number of diagnosed preeclamptic
patients that delivered by unplanned cesarean section was 0. Three of these
patients delivered vaginally (previous successful vaginal deliveries) and one
patient delivered by repeat cesarean section. After algorithm implementation, two
patients delivered by unplanned cesarean section, and one patient delivered
vaginally. Of these three patients, the two patients who delivered by unplanned
cesarean section were not treated with the algorithm. The one patient who was
treated using the algorithm had a vaginal delivery. One patient who didn’t receive
appropriate treatment was admitted to Intensive Care Unit with a diagnosis of
Pulmonary Edema.
Conclusion
When the Labetalol algorithm was followed during this project (both pre
and post implementation period), there was a greater improvement in blood
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pressure measurements compared to the patients who were treated with individual
physician orders. The pre and post implementation data in this project doesn’t
give an accurate representation of how effective the algorithm is due to
noncompliance from physicians. Some attending physicians also used the
algorithm under their own volition prior to unit wide implementation which also
affected the retrospective chart review. Post implementation data demonstrated
that when healthcare personnel don’t use the Labetalol algorithm, the potential for
unplanned cesarean sections occur more frequently, as well as maternal
complications, such as ICU admissions.
This project should be completed again with education for both nursing
personnel and physicians prior to implementation. Data should also be collected
for longer periods of time due to the small sample size at this facility. It is critical
for healthcare personnel to understand the importance of adopting and following
algorithms and protocols in order to increase patient safety. There is a need for
further education for all healthcare personnel regarding hypertensive disorders of
pregnancy, diagnostic criteria, monitoring of these patients, and treatment using
recommended protocols. As mentioned earlier, Clark et al.’s report (2014)
showed a significant reduction in morbidity when order sets and protocols were
implemented in facilities. Nursing staff play an integral role in the assessment
and treatment of hypertensive patients during pregnancy. Once they assess the
patient and determine that treatment is warranted, it is their responsibility to
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contact the physician, report critical values, and recommend evidence-based
treatment. ACOG is an organization that is dedicated to the improvement of
women’s health and encourages obstetricians to implement best practice. The
Labetalol algorithm is recommended by ACOG for the treatment of preeclamptic
patients.
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Figure 1. Method of Delivery Pre-Implementation.
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Appendix B
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Figure 2. Average Effect on Blood Pressure Pre-Implementation.
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Appendix C
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Figure 3. Timing of Onset of Treatment Pre-Implementation (minutes).
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Figure 4. Method of Delivery Post-Implementation.
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Figure 5. Average Effect on Blood Pressure Post-Implementation.
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Figure 6. Timing of onset of Treatment Post-Implementation (minutes).
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Figure 7. Rate of Labetalol Algorithm use Pre-Implementation.
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Figure 8. Rate of Labetalol Algorithm use Post-Implementation.

